Dr. Christopher Jones, U.S. Public Health Service and Centers for Disease Control and Prevention (CDC), reviews current options (to include methadone, buprenorphine and naltrexone) in Medication-Assisted Treatment (MAT) for those with an opioid use disorder.

In concluding remarks, Judge Irene Keeley (N.D. W.

In 2019, the residual hearsay exception, Federal Rules of Evidence 807, was amended to fix a number of problems that courts had encountered applying the rule.

This package of materials was transmitted to Congress on April 25, 2019, concerning amendments to the Federal Rules of Practice and Procedure to become effective on December 1, 2019.

Amendments to the Federal Rules of Practice and Procedure are as follows: